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Bronchial brushing is a useful method for morphological and functional studies of bronchial epithelial cells (BECs) 
in various diseases. This technique has been found to be generally safe, but its safety in asthma and chronic 
bronchitis has not been fully assessed. The purpose of this study was to determine 1. whether bronchial brushing is 
a safe method in asthmatic and chronic bronchitis patients of differing severity and 2. to characterize the BECs 
obtained in terms of number, viability and purity. We evaluated 25 asthmatics of variable severity, 19 chronic 
bronchitis patients and 26 normal volunteers. Bronchoscopy and bronchial brushing were performed in a 
standardized manner by the same investigator. Safety was assessed by clinical follow-up of all subjects; continuous 
monitoring of arterial oxygen saturation during the procedure with a digital oximeter was carried out in a subsample 
of subjects. No complications were observed clinically during the procedure. There was a minimal fall in arterial 
oxygen saturation without a significant difference between the three groups of subjects. A consistent number of 
BECs was recovered and their viability, assessed by the trypan blue exclusion test, in asthmatics and chronic 
bronchitis patients was significantly lower than in controls (PcO.05). Bronchial brushing is well tolerated and may 
be a valuable method of obtaining BECs in asthmatic and chronic bronchitis patients. 
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Introduction 
Bronchial epithelial cells (BECs) can be studied using 
several methods. Explants can be obtained from fibre-optic 
biopsies, open lung biopsies or at autopsy (I), but BECs are 
attached to the basement membrane and the submucosa 
and it is difficult to ascribe mediator release to a particular 
cell type. Protease treatment of bronchial mucosa can yield 
BECs with a high viability, but these cells then must be 
separated from other cell types using various methods (2,3). 
If culture techniques are used, the cells may de-differentiate 
(4,5) and lose some of their phenotypic characteristics, such 
as the presence of cilia, although some methods make it 
possible to cultivate cells with cilia for several days (6,7). 
Bronchial brushing is another technique to recover BECs 
which was found to be of interest (8-12). 
Bronchial brushing has been found to be generally safe, 
but unusual complications have been reported (13,14). In 
asthma, bronchial brushing has been used to study BECs 
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(8,10,12,15) and inflammatory cells infiltrating the epi- 
thelium or present at the surface of the epithelial layer (16). 
We studied whether bronchial brushing is a safe method 
in asthmatic patients of variable severity and chronic 
bronchitis patients and characterized the BECs in terms of 
number, viability and purity to assess whether brushing 
yields sufficient numbers of viable BECs. 
Methods 
PATIENTS 
Twenty-five asthmatic subjects (aged 23-75 years, median 
53 years; 16 men) were studied (Table 1). Asthma was 
defined according to the American Thoracic Society criteria 
(17). All had a reversibility of the airways obstruction of at 
least 12% of forced expiratory volume in 1 set (FEV,) from 
baseline and an absolute value of 200 ml (18). Clinical 
severity of asthma was assessed according to the validated 
Aas score, which grades the different forms of chronic 
asthma from mild (score 1) to very severe (score 5). None of 
the subjects participating in this study was a current or 
previous smoker. No subject had any bronchial or respir- 
atory tract infection during the month preceding the test. 
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TABLE 1. Demographic and clinical characteristics of subjects 
Asthma Chronic bronchitis 
(n=25) (n=19 
Control 
(n=26) 
Age (years) 
Sex 
FEV, 
Allergy 
Treatment 
Smoker 
53(23-75) 
16M; 9F 
80(45-121)" 
52% 
&agonists as required 
No 
56(42-75) 
16M; 3F 
65 (40-95)"" 
None 
None 
(30-l 50) pack/year 
51(25-78) 
21M; 5F 
100(87-125) 
None 
None 
No 
Results are expressed as median and range. 
*P<O,O5; **P<O.Ol; significant differences compared to control (Mann-Whitney U-test). 
All patients were without any medication for at least 
1 month, except for &agonists as required. Their atopic 
status was defined as previously reported (17). 
Nineteen chronic bronchitis patients (aged 42-15 years, 
median 56; 16 men) were studied. Chronic bronchitis was 
defined according to the American Thoracic Society criteria 
(19). Chronic obstructive pulmonary disease (COPD) was 
defined as a disorder characterized by abnormal results in 
expiratory flow tests (19). As an overlap between chronic 
bronchitis and asthma may occur in subjects with so-called 
‘asthmatic bronchitis’, patients showing one of the follow- 
ing features were excluded: a history of perennial allergic 
rhinitis and/or a positive diagnosis of immediate type 
hypersensitivity (17); an improvement of FEV, capacity of 
over 12% from baseline and an absolute value of 200 ml 
following inhalation of 2OOpg of salbutamol (18). Smoking 
habits were carefully checked and a minimum of 30 pack 
years smoked was required for inclusion in the chronic 
bronchitis group (range 30-150 pack years, median 61 pack 
years). Patients were not studied during exacerbations and 
no subject had any bronchial or respiratory tract infection 
during the month preceding the test, Patients were excluded 
from the study if they had taken any drug except for 
&agonists as required. 
Twenty-six healthy subjects (aged 25-78 years, median 51 
years; 21 men) were used as a control group. Their pulmon- 
ary function was within normal range, they were non- 
allergic, had never suffered from asthma or chronic 
bronchitis and none of them was a previous smoker. No 
member of the control group had suffered from any respir- 
atory tract infection during the month preceding the test. 
The study was performed after informed consent from 
the participants and approval of the Ethics Committee of 
the University of Montpellier had been obtained. 
PULMONARY FUNCTION 
Pulmonary function was assessed by measuring forced vital 
capacity (FVC) and FEV, just before and 5 min after 
bronchoscopy. This was assessed by means of a flow- 
volume loop, using a Fukuda ST 250 (Emo International, 
Dompierre-sur-Mer, France), and normal values were 
defined according to the standards of Knudson (20). 
BRONCHIAL BRUSHING 
Fibre-optic bronchoscopy was performed as previously 
described (17). Briefly, after premeditation with 0.5 mg 
atropine and 5 mg diazepam and local anaesthesia with 2% 
lignocaine applied to the upper respiratory tract, a BFTR 
Olympus fibre-optic bronchoscope (Olympus, Paris, 
France) was inserted into the trachea and the airways were 
systematically examined. Lignocaine was not applied to the 
lower respiratory tract in any case as it may alter cell 
function (9). The cough entity observed was not more 
significant than in bronchoscopies routinely performed with 
local anaesthesia in the lower respiratory tract. During 
bronchoscopy, oxygen and epinephrine were readily 
available and the patient had an intravenous infusion to 
provide venous access. Nebulization with 1 mg of salbuta- 
mol was performed systematically in asthmatics 15 min 
after the end of the procedure. Brushing was performed in a 
standardized manner by the same investigator according to 
a previously published method (10,12:15). The brush, a 
5-mm sheathed and reusable protected brush, Model BC- 
1OC (Olympus, Paris, France), was introduced via the fibre- 
optic bronchoscope into the subsegmental bronchi of the 
left lower lobe. Brushing was performed in two different 
sites on the lobe with 10 gentle upward and downward 
strokes. The airways were brushed from the distal to the 
proximal parts of the subsegment, in order to avoid losing 
visual contact with the brush. The duration of the whole 
bronchoscopy procedure was about 8-10 min. The brush 
was then placed into a sterile conical tube containing sterile 
medium and the cells were resuspended by gentle vortexing 
of the tubes. All subjects were observed for 3 h and were 
given a contact telephone number. 
ASSESSMENT OF SAFETY OF BRUSHING 
During bronchoscopy, eventual symptoms were carefully 
monitored in all patients and the arterial oxygen saturation 
was continually monitored in 11 asthmatics, 13 COPD 
patients and 12 healthy subjects, using a digital oximeter 
(Satlite Plus, France). Eight defined time-points were 
used for study. Tl and T2 were respectively defined by 
the beginning and the end of atropine and diazepam 
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premeditation and local anaesthesia with lignocaine. T3 
corresponded to the introduction of the fibre-optic 
bronchoscope into the nose. T4 was the time just after the 
passage through the vocal cords. T5 and T6 were defined by 
the beginning and the end of the bronchial brushing, 
respectively. T7 was defined as the end of the fibre-optic 
bronchoscopy. T8 corresponded to 5 min after the end of 
the procedure. 
CYTOLOGY OF BRUSHING 
The cells collected were separated by vortexing the brush 
for several seconds into 1.5 ml conical tubes containing 
RPM1 1640 and antibiotics (penicillin 100 U/ml-‘, coli- 
mycin 100 U/ml-‘, gentamycin .50~glml-1, and 
fungizone 10 yglml - ‘). This procedure dispersed the BECs 
efficiently, which were subsequently pelleted by centrifuga- 
tion at 400 x g for 10 min. Finally, cells were resuspended 
in 1 ml RPM1 for the evaluation of their number, viability 
and origin. 
Cell viability was evaluated using the Trypan blue 
exclusion test. Fixed preparations were prepared using 
a cytocentrifuge (Shandon Southern Products, Ltd., 
Runcorn, Cheshire, U.K.). Slides were stained with 
May-Grunwald-Geimsa to allow morphological identifica- 
tion of cell types. The assessment of each slide was per- 
formed twice by two different observers in a double-blinded 
manner. The results are presented as the mean of four 
assessments. 
STATISTICAL ANALYSIS 
Results are reported as median and range or mean f SD. 
Data were analysed using analysis of variance (ANOVA), 
followed by the Mann-Whitney U-test for multiple com- 
parisons. Significance was assigned at PcO.05. Correlations 
were tested using Spearman’s rank-correlation coefficient. 
Results 
CHARACTERISTICS OF SUBJECTS 
The characteristics of the normal subjects and asthmatic 
and chronic bronchitis patients are presented in Table 1. 
There was no significant difference in the mean age of 
patients and control subjects. The pulmonary function of 
patients with asthma as assessed by FEV, ranged from 45 
to 121% of predicted value (median 80% from predicted). 
The severity of asthma ranged from mild to moderately 
severe (Aas score 1: 10 patients; Aas score 2: five patients; 
Aas score 3: six patients; Aas score 4: four patients). 
Thirteen of the asthmatic patients were allergic to perennial 
allergens. The FEV, values of chronic bronchitis patients 
ranged from 40 to 95% (median 65% from predicted). The 
pulmonary function of healthy subjects was normal 
(median 100% of predicted). The median FEV, values of 
asthmatic and chronic bronchitis patients were significantly 
lower than those of the normal group (P<O.OOl). 
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FIG. 1. Arterial oxygen saturation was monitored using 
digital oximeter at eight different times as follows: Tl and 
T2 defined the beginning and the end of atropine and 
diazepam premeditation and local anaesthesia with 
lignocaine; T3 corresponded to the introduction of the 
fibre-optic bronchoscope into the nose; T4 was the time 
just after the passage through the vocal cords; T5 and T6 
were defined by the beginning and the end of the 
bronchial brushing, respectively; T7 was defined as the 
end of the fibre-optic bronchoscopy; TS responded to 
5 min after the procedure. The results are given as median 
and SD and a non-significant difference was observed. 
(A, Asthmatics; 0, chronic bronchitis patients; 
0, controls.) 
SAFETY 
None of the patients or control subjects presented 
symptoms or significant bleeding during the procedure (no 
requirement for cold water or adrenaline). The procedure 
was always carried out fully in all subjects. A minimal fall 
was observed in arterial saturation (Fig. 1) without signifi- 
cant difference between the three groups of subjects. No 
asthma exacerbation was observed and no significant bleed- 
ing was reported clinically just after or up to 24 h after the 
procedure. 
VIABILITY OF CELLS RECOVERED 
The viability of the epithelial cells as assessed by trypan 
blue exclusion is shown in Table 2 and Fig. 2. There 
was a significant decrease in cell viability in asthmatic 
patients (PcO.05) and in chronic bronchitis patients 
(PcO.05) as compared to control subjects. There was no 
significant difference between the two groups of patients, 
No correlation was found between the viability of the 
epithelial cells and FEV, or Aas score (Spearman’s rank 
test). 
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TABLE 2. Viability and cytology of cells recovered from bronchial brushing 
Asthmatics Chronic bronchitis Controls 
Total cells (10’) 
Viability (%) 
Macrophages (%j 
Neutrophils (%) 
Lymphocytes (%) 
Eosinophils (%j 
Epithelial cells (%) 
Squamous cells (“Yo) 
2.38 (0.0840) 0%4(0.09-8.80) 1.16 (0.4-800) 
18.0(2-54)* 11.0 (10-70)” 32.5 (10-57) 
8.0 (l-40) 4.0 (O-l 8) 4.5 (O-28) 
0 (O-22) 2.0(0-14) 1 ,O (O-25) 
0 (o-i 1) 0 (O-10) 1 (O-15) 
O(O-3) 0 (O-l) O(O-2) 
X5(56-98) 88(58-98) 90(57-97) 
0(0-6) 2(0-12) 0 (O-13) 
Results are expressed as median and range. 
*P<O.O5, significant difference compared to control subjects (Mann-Whitney U-test). 
CYTOLOGY 
BECs represented 85% of the total cells recovered from the 
brushing (Table 2). Although the number of cells recovered 
in chronic bronchitis patients was less than that in 
asthmatic patients, this difference did not reach signifi- 
cance. Moreover, no significant differences were observed in 
the percentages of contaminating cells in the brushing. No 
correlations were found between the percentage of BECs 
recovered and the FEV, or Aas score. 
Discussion 
In this study we assessed the safety of bronchial brushing in 
normal subjects, asthmatic patients of varying severity and 
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FIG. 2. Viability of bronchial epithelial cells was assessed 
by the trypan blue exclusion test, Values of PcO.05 were 
taken as significant between control subjects and 
asthmatic or chronic bronchitis patients. No significant 
difference was found between the groups of patients with 
disease. 
chronic bronchitis patients, without premeditation with a 
nebulized bronchodilatator. We also evaluated the number 
and viability of the recovered BECs and the degree of 
contamination of the specimens. 
Our results show that bronchial brushing is a well 
tolerated and safe method of obtaining BECs in asthmatics 
and chronic bronchitis patients, as shown by the minimal 
fall in arterial saturation during the procedure, which was 
not significantly different between the three groups of 
subjects. To our knowledge, this is the first study to 
evaluate the safety of this technique in patients with airflow 
obstruction. We did not perform 0, saturation testing in all 
patients at all time points as we did not observe any 
significant fall in the studied subjects and because we have 
found previously, in a larger number of asthmatics, that 
bronchoscopy is usually well tolerated. We have previously 
demonstrated the safety of bronchoalveolar lavage and 
bronchial biopsies in asthmatic patients of varying severity 
(21). In the present study, we observed that bronchial 
brushing was well tolerated because serious complications 
were not observed, respiratory symptoms did not occur 
even in severe asthmatic patients and in no case did we have 
to stop the procedure. Our findings indicate that the clinical 
severity of asthma assessed by the Aas score and of chronic 
bronchitis assessed by basal FEV, are not associated with 
the occurrence of adverse side-effects. The airflow obstruc- 
tion in most of our patients precluded a pharmacological 
challenge to assess bronchial hyperresponsiveness which 
has been shown to be related to fibre-optic tolerance in 
asthma (22). 
The brushed cells issue from the upper part of the 
epithelial layer and we were able to show in surgical 
specimens that only basal cells remained after in vitro 
brushing (unpubl. obs.). The total number of cells was not 
significantly different between the groups of patients. In 
normal volunteers and patients with bronchial diseases, 
three to six brushings were generally performed 
(10,15,23). Some authors have reported a procedure 
duration of 25 min in normal subjects, with a higher 
recovery of cells (9). For safety reasons, this procedure 
length cannot be recommended in patients with bronchial 
diseases. 
As previously described (lo), we found that viability of 
the epithelial cells, as assessed by Trypan blue exclusion, 
was significantly lower in asthmatics than in controls. 
Moreover, in this study we also found a lower viability in 
chronic bronchitis patients in comparison to controls. A 
bronchial biopsy was obtained at the time of the brushing 
in four different subjects. Biopsies were placed in fresh 
RPM1 medium and were disrupted using a fine Pasteur 
pipette with hard pipetting for 1 min. The viability of the 
detached cells recovered was assessed and found to be the 
same as that of the cells obtained by brushing. It is 
important to take into account the effect of local 
anaesthesia on the viability of BECs, as the viability of 
BECs has been shown to be directly related to the amount 
of lignocaine used (9). Some authors have advocated 
brushing segmental airways after a bronchial wash to 
remove lignocaine and avoid airway contamination with 
inflammatory cells (24). However, we used only small 
amounts of local anaesthesia before performing 
bronchoscopy and lignocaine was not used in the airway 
segments investigated. We suggest that the low viability of 
the BECs obtained by brushing the airways could be 
related to the inflammation of the airways, indicating a 
crucial role for the epithelium in such circumstances. The 
reasons why BECs should be poorly viable in brushings 
from asthmatic and chronic bronchitis patients are not 
clear and may be related to the frequently reported 
fragility of epithelium (25-28). Eosinophil-derived 
products may be involved as eosinophil cationic protein 
(ECP) may be involved in the shedding of epithelial cells 
in asthmatics (17) and in vitro studies have suggested a 
role for major basic protein (MBP) (29). 
In most instances, bronchial brushing recovered mainly 
BECs; the other contaminating cells were macrophages 
and neutrophils. Eosinophils were rarely recovered but 
were detectable in some patients in the three groups 
without significant differences between them. This result 
differs from other studies (10,15) in which eosinophils 
were absent and a recent study (30) in which an increased 
percentage of eosinophils in steroid-untreated asthmatic 
patients was found in comparison with asthmatics on 
regular medication with inhaled steroids and patients with 
non-obstructive chronic bronchitis. We were unable to 
find any relationship between this eosinophilic component 
and any clinical or functional parameter of the bronchial 
disease. However, bronchial brushing eosinophilia is not 
as important as it is reported to be in other bronchial 
sampling methodologies such as sputum, bronchial wash 
or BAL. Bronchial brushing does not appear to be the 
sampling method of choice to investigate inflammatory 
cells in bronchial disease, although some authors 
have reported differences between control subjects and 
asthmatic patients. 
The present study demonstrates that bronchial brushing 
is feasible and safe in patients with various bronchial 
diseases of varying severity. The main purpose of this 
sampling technique is to study BECs. The poor viability 
of such cells found in asthma and chronic bronchitis 
suggests an active role in the pathophysiology of these 
diseases. 
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